At KPMG, we are assisting clients working at the forefront of the next generation of therapies - cell and gene technologies. While these technologies are transforming patient care for certain diseases, they also bring their own unique complexities. KPMG brings a holistic view to the challenges and opportunities associated with the development, manufacturing, supply, pricing, and commercialization of these therapies. We continue to support clients, from small biotechs to large biopharma, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and also private investors, to help them successfully negotiate these challenges and seize the opportunities that cell and gene therapies present.